EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
-20.16%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$216M
AUM Growth
+$216M
(-24%)
Cap. Flow
+$13.4M
Cap. Flow
% of AUM
6.18%
Top 10 Holdings %
Top 10 Hldgs %
82.29%
Holding
30
New
5
Increased
7
Reduced
4
Closed
4
Top Buys
| 1 |
Travere Therapeutics
TVTX
|
$13.5M |
| 2 |
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
|
$7.94M |
| 3 |
Assembly Biosciences
ASMB
|
$2.99M |
| 4 |
CASC
Cascadian Therapeutics, Inc.
CASC
|
$2.59M |
| 5 |
AKTX
Akari Therapeutics
AKTX
|
$2.42M |
Top Sells
| 1 |
Atara Biotherapeutics
ATRA
|
$8.17M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
$2.88M |
| 3 |
EPZM
Epizyme, Inc
EPZM
|
$2.48M |
| 4 |
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
|
$2M |
| 5 |
Seres Therapeutics
MCRB
|
$1.66M |
Sector Composition
| 1 | Healthcare | 76.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Bausch Health
BHC
$2.72B
| – | – |
0
| – | – |
|
27
Gilead Sciences
GILD
$140B
| – | – |
0
| – | – |
|
|
28
Seres Therapeutics
MCRB
$162M
| – | – |
-40,000
| Closed | -$1.66M |
|
|
RGLS
29
DELISTED
Regulus Therapeutics
RGLS
| – | – |
0
| – | – |
|